Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?

Cancer and Metastasis Reviews

Volumn 19, Issue 1-2, 2000, Pages 83-86

  Gingras, Denis ^a   Renaud, Alain ^a   Mousseau, Nathalie ^a   Béliveau, Richard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

AE 941; Angiogenesis; Cancer; Matrix metalloproteinase; Shark cartilage

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CARTILAGINOUS TISSUE; CELL PROLIFERATION; DRUG EFFECT; EXTRACTION; GROWTH INHIBITION; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHARK; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CARTILAGE; CLINICAL TRIALS, PHASE III; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SHARKS; TISSUE EXTRACTS;

EID: 0034528012     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026504500555     Document Type: Review

References (33)

1. The treatment of human cancer with agents prepared from bovine cartilage
2. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer
3. The resistance of certain tissues to invasion: Penetrability of explanted tissues by vascularized mesenchyme
4. The resistance of certain tissue to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture
5. Cancer in sharks, skates, rays and other lower fishes
6. The resistance of certain tissues to invasion. II. Evidence of extractable factors in cartilage which inhibit invasion by vascularized mesenchyme
7. Tumor angiogenesis: Therapeutic implications
8. Anti-angiogenesis: New concept for therapy of solid tumors
9. Tumor angiogenesis
10. Inhibition of tumor angiogenesis mediated by cartilage
11. Isolation of a cartilage factor that inhibits tumor neovascularization
12. Control of tumor growth in animals by infusion of an angiogenesis inhibitor
13. Shark cartilage contains inhibitors of tumor angiogenesis
14. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium
15. A novel angiogenic inhibitor derived from Japanese shark cartilage (1). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis
16. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and antitumor activities
17. Inhibition of new blood vessel formation in mice by systemic administration of human rib cartilage extract
18. Identification of an inhibitor of neovascularization from cartilage
19. A metalloproteinase inhibitor as an inhibitor of neovascularization
20. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes
21. Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8
22. Tumor cell collagenase and its inhibition by a cartilage derived protease inhibitor
23. Purification and partial amino acid sequence of bovine cartilage-derived collagenase inhibitor
24. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultures chondrocytes
25. Troponin I is present in human cartilage and inhibits angiogenesis
26. Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding
27. Angiostatic activity of Neovastat (AE-941) assessed by a semi-quantitative embryonic vascularization test
28. In vitro and in vivo anti-tumor activity of Neovastat (AE-941), an angiostatic agent derived from shark cartilage
29. Antiangiogenic agent AE-941 induces in vivo and in vitro inhibition of VEGF
30. AE-941, a new and specific VEGF antagonist?
31. AE-941 (Neovastat): An inhibitor of angiogenesis with anti-cancer activity
32. Phase I/II clinical trials of escalating dose of AE-941, an inhibitor of angiogenesis in patients with refractory lung cancer